Company: RCUS
Filing Date: 2025-10-14
Form Type: 8-K
Source: 0001724521-25-000109
Chunk: 0

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-14
Form: 8-K
Item: Item 8.01
Chunk 0
---
 (45%, 87%)  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  One patient did not have tissue available for central laboratory TAP scoring (SP263 assay). Local lab results showed the patient was PD-L1 low according to 22C3 assay.                                                                                  

No unexpected safety signals were observed at the time of data cut off. The safety profile of domvanalimab plus zimberelimab and chemotherapy was generally well tolerated and is consistent with that of anti-PD-1 plus chemotherapy. Immune-mediated TEAEs related to domvanalimab and/or zimberelimab occurred in 9 patients (22%), and infusion-related reactions occurred in 3 patients (7%).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                              ARCUS BIOSCIENCES, INC.                                     
  Date: October 14, 2025      By:                          /s/ Terry Rosen, Ph. D.        
                                                           Terry Rosen, Ph. D.            
                                                           Chief Executive Officer